TradingKey

關於 Dynavax Technologies Corp 公司

Dynavax Technologies Corporation 是一家商業階段生物製藥公司，致力於開發和商業化疫苗。該公司的產品包括 HEPLISAV-B 乙肝疫苗和 CpG 1018。其 HEPLISAV-B（重組）（佐劑）用於預防 18 歲及以上成人中所有已知乙肝病毒亞型引起的感染。HEPLISAV-B 是一種兩劑成人乙肝疫苗。該公司還生產和銷售 CpG 1018 佐劑，即 HEPLISAV-B 中使用的佐劑。該公司還致力於開發利用 CpG 1018 佐劑的多項目臨牀管線，以開發針對未滿足醫療需求的適應症的改良疫苗。其管線項目包括正在開發的帶狀皰疹、破傷風、白喉和百日咳 (Tdap) 和鼠疫的候選疫苗。其帶狀皰疹疫苗項目 Z-1018 是一種正在開發的用於預防 50 歲成人帶狀皰疹的試驗性候選疫苗及以上。

公司簡介

公司代碼DVAX

公司名稱Dynavax Technologies Corp

上市日期Feb 19, 2004

CEOMr. Ryan Spencer

員工數量405

證券類型Ordinary Share

年結日Feb 19

公司地址2100 Powell Street

城市EMERYVILLE

上市交易所NASDAQ Global Select Consolidated

國家United States of America

郵編94608

電話15108485100

網址https://www.dynavax.com/

公司代碼DVAX

上市日期Feb 19, 2004

CEOMr. Ryan Spencer

公司高階主管

名稱

名稱/職務

職務

持股

持股變動

Mr. Ryan Spencer

Chief Executive Officer, Director

277.67K

--

Dr. Robert (Rob) Janssen, M.D.

Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs

74.92K

--

Mr. David F. Novack

President, Chief Operating Officer

56.05K

+33.36%

Mr. John L. Slebir

Senior Vice President, General Counsel

31.42K

--

Ms. Elaine D. Sun

Independent Director

29.86K

+23.89%

Ms. Kelly MacDonald, CPA

Chief Financial Officer, Senior Vice President

25.52K

--

Dr. Peter R. Paradiso, Ph.D.

Independent Director

24.83K

+30.19%

Dr. Daniel L. (Dan) Kisner, M.D.

Independent Director

23.33K

+32.77%

Mr. Brent MacGregor

Independent Director

21.83K

+35.83%

Dr. Emilio Emini

Independent Director

1.44K

--

名稱

名稱/職務

職務

持股

持股變動

Mr. Ryan Spencer

Chief Executive Officer, Director

277.67K

--

Dr. Robert (Rob) Janssen, M.D.

Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs

74.92K

--

Mr. David F. Novack

President, Chief Operating Officer

56.05K

+33.36%

Mr. John L. Slebir

Senior Vice President, General Counsel

31.42K

--

Ms. Elaine D. Sun

Independent Director

29.86K

+23.89%

Ms. Kelly MacDonald, CPA

Chief Financial Officer, Senior Vice President

25.52K

--

收入明細

單位: USD更新時間: 7月6日週日

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

業務USD

名稱

營收

佔比

HEPLISAV-B

64.96M

95.30%

Other revenue

3.21M

4.70%

地區USD

名稱

營收

佔比

US

67.81M

99.47%

Non-US

358.00K

0.53%

業務

地區

業務USD

名稱

營收

佔比

HEPLISAV-B

64.96M

95.30%

Other revenue

3.21M

4.70%

股東統計

更新時間: 5月17日週六

持股股東

股東類型

持股股東

佔比

BlackRock Institutional Trust Company, N.A.

15.53%

Deep Track Capital LP

14.82%

The Vanguard Group, Inc.

7.22%

State Street Global Advisors (US)

5.65%

Tang Capital Management, LLC

4.79%

Other

51.99%

持股股東

佔比

BlackRock Institutional Trust Company, N.A.

15.53%

Deep Track Capital LP

14.82%

The Vanguard Group, Inc.

7.22%

State Street Global Advisors (US)

5.65%

Tang Capital Management, LLC

4.79%

Other

51.99%

股東類型

持股股東

佔比

Investment Advisor

40.52%

Hedge Fund

38.07%

Investment Advisor/Hedge Fund

21.73%

Research Firm

5.56%

Pension Fund

1.34%

Individual Investor

0.59%

Sovereign Wealth Fund

0.57%

Bank and Trust

0.55%

Venture Capital

0.06%

機構持股

更新時間: 7月1日週二

報告期間

機構數

持股數

持股佔比

持股變動

2025Q2

551

130.99M

109.09%

-16.02M

2025Q1

575

132.57M

110.30%

-15.70M

2024Q4

565

133.92M

107.04%

-18.98M

2024Q3

561

132.88M

101.45%

-18.82M

2024Q2

547

135.21M

103.33%

-14.69M

2024Q1

545

136.49M

104.51%

-4.07M

2023Q4

529

128.50M

99.42%

-9.47M

2023Q3

515

128.65M

99.89%

-9.14M

2023Q2

503

129.32M

100.65%

-12.27M

2023Q1

497

129.65M

101.54%

-1.28M

股東持股明細

名稱

持股數

佔比

持股變動

變動比例

公告日期

BlackRock Institutional Trust Company, N.A.

18.65M

15.53%

-799.41K

-4.11%

Mar 31, 2025

Deep Track Capital LP

17.79M

14.82%

--

Mar 31, 2025

The Vanguard Group, Inc.

8.67M

7.22%

-459.90K

-5.04%

Mar 31, 2025

State Street Global Advisors (US)

6.79M

5.65%

-1.00M

-12.88%

Mar 31, 2025

Tang Capital Management, LLC

5.75M

4.79%

+3.90M

+210.81%

Mar 31, 2025

Chicago Capital, LLC

5.34M

4.45%

-36.81K

-0.68%

Mar 31, 2025

Deerfield Management Company, L.P.

5.19M

4.32%

-2.33K

-0.04%

Mar 31, 2025

Dimensional Fund Advisors, L.P.

4.01M

3.34%

-58.27K

-1.43%

Mar 31, 2025

Geode Capital Management, L.L.C.

3.07M

2.55%

+71.47K

+2.39%

Mar 31, 2025

Renaissance Technologies LLC

2.71M

2.25%

+350.25K

+14.87%

Mar 31, 2025

持股ETF

更新時間: 8月2日週六

機構名稱

佔比

Invesco Biotechnology & Genome ETF

2.7%

Virtus LifeSci Biotech Products ETF

1.84%

Pacer US Small Cap Cash Cows Growth Leaders ETF

1.15%

ETC 6 Meridian Small Cap Equity ETF

0.79%

Invesco S&P SmallCap Health Care ETF

0.79%

Franklin Genomic Advancements ETF

0.64%

Themes US Small Cap Cash Flow Champions ETF

0.45%

SPDR S&P Biotech ETF

0.41%

Royce Quant Small-Cap Quality Value ETF

0.32%

ETC 6 Meridian Low Beta Equity Strategy ETF

0.29%

Invesco Biotechnology & Genome ETF

佔比2.7%

Virtus LifeSci Biotech Products ETF

佔比1.84%

Pacer US Small Cap Cash Cows Growth Leaders ETF

佔比1.15%

ETC 6 Meridian Small Cap Equity ETF

佔比0.79%

Invesco S&P SmallCap Health Care ETF

佔比0.79%

Franklin Genomic Advancements ETF

佔比0.64%

Themes US Small Cap Cash Flow Champions ETF

佔比0.45%

SPDR S&P Biotech ETF

佔比0.41%

Royce Quant Small-Cap Quality Value ETF

佔比0.32%

ETC 6 Meridian Low Beta Equity Strategy ETF

佔比0.29%

分紅派息

近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股

公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

Dynavax Technologies Corp

10.860USD

Dynavax Technologies Corp

10.860

概覽

公司

財務